American Journal of Ophthalmology
Volume 149, Issue 3 , Pages 441-446.e2 , March 2010

Association Between the Efficacy of Photodynamic Therapy and Indocyanine Green Angiography Findings for Central Serous Chorioretinopathy

,Accepted 12 October 2009.

References 

  1. Gass JDM. Idiopathic Central Serous Chorioretinopathy: Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment. In: 4th ed.. St. Louis: CV Mosby; 1997;p. 52–70
  2. Spaide RF. Central serous chorioretinopathy. In:  Holz FG,  Spaide RF editor. Medical Retina (Essentials in Ophthalmology series). Berlin: Springer-Verlag; 2004;p. 77–93
  3. Levine R, Brucker AJ, Robinson F. Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology. 1989;96:854–859
  4. Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol. 1994;112:1057–1062
  5. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol. 1996;121:26–34
  6. Scheider A, Nasemann JE, Lund OE. Fluorescein and indocyanine green angiographies of central serous choroidopathy by scanning laser ophthalmoscopy. Am J Ophthalmol. 1993;115:50–56
  7. Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994;14:231–242
  8. Spaide RF, Hall H, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996;16:203–213
  9. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography–guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23:288–298
  10. Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003;23:752–763
  11. Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87:1453–1458
  12. Piccolino FC, Borgia L, Zinicola E, Zingirian M. Indocyanine green angiographic findings in central serous chorioretinopathy. Eye. 1995;9:324–332
  13. Iida T, Kishi S, Hagimura N, Shimizu K. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina. 1999;19:508–512
  14. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Arch Ophthalmol. 1999;117:1329–1345
  15. Fujimoto H, Gomi F, Wakabayashi T, et al. Morphologic changes in acute central serous chorioretinopathy evaluated by Fourier-domain optical coherence tomography. Ophthalmology. 2008;115:1494–1500
  16. Chan WM, Lai TY, Lai RY, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina. 2008;28:85–93
  17. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy one-year results of a randomized controlled trial. Ophthalmology. 2008;115:1756–1765

 See Accompanying Editorial on page 361.

PII: S0002-9394(09)00793-4

doi: 10.1016/j.ajo.2009.10.011

American Journal of Ophthalmology
Volume 149, Issue 3 , Pages 441-446.e2 , March 2010

Article Tools

* Image Usage & Resolution